IGHE and Alzheimer disease: Both of them were up-regulated in AD mice, as compared with that of normal mice (P<0.05 for both, Fig. 4D and Fig. 4E), and BSYQ (13g/kg and 26g/kg) treatment significantly reduced the serum levels of OVA-IgE in a dose-dependent manner, as compared with that of AD control mice (P<0.05 for both, Fig. 4D and Fig. 4E).